<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vavilov</journal-id><journal-title-group><journal-title xml:lang="ru">Вавиловский журнал генетики и селекции</journal-title><trans-title-group xml:lang="en"><trans-title>Vavilov Journal of Genetics and Breeding</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2500-3259</issn><publisher><publisher-name>Institute of Cytology and Genetics of Siberian Branch of the RAS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18699/vjgb-25-82</article-id><article-id custom-type="elpub" pub-id-type="custom">vavilov-4802</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МОЛЕКУЛЯРНАЯ И КЛЕТОЧНАЯ БИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MOLECULAR AND CELL BIOLOGY</subject></subj-group></article-categories><title-group><article-title>Интерактом белка HOXB13 в клетках рака простаты: биохимические и функциональные взаимодействия между транскрипционными факторами HOXB13 и TBX3</article-title><trans-title-group xml:lang="en"><trans-title>HOXB13 interactome in prostate cancer cells: biochemical and functional interactions between the transcription factors HOXB13 and TBX3</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ерохин</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Erokhin</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Москва </p></bio><bio xml:lang="en"><p> Moscow </p></bio><email xlink:type="simple">yermaxbio@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козельчук</surname><given-names>Н. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozelchuk</surname><given-names>N. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Москва </p></bio><bio xml:lang="en"><p> Moscow </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зиганшин</surname><given-names>Р. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Ziganshin</surname><given-names>R. H.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Москва </p></bio><bio xml:lang="en"><p> Moscow </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Татарский</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tatarskiy</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Москва </p></bio><bio xml:lang="en"><p> Moscow </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Четверина</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Chetverina</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Москва </p></bio><bio xml:lang="en"><p> Moscow </p></bio><email xlink:type="simple">daria.chetverina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Институт биологии гена Российской академии наук<country>Россия</country></aff><aff xml:lang="en">Institute of Gene Biology of the Russian Academy of Sciences<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук<country>Россия</country></aff><aff xml:lang="en">Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>10</month><year>2025</year></pub-date><volume>29</volume><issue>6</issue><fpage>744</fpage><lpage>752</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ерохин М.М., Козельчук Н.Я., Зиганшин Р.Х., Татарский В.В., Четверина Д.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ерохин М.М., Козельчук Н.Я., Зиганшин Р.Х., Татарский В.В., Четверина Д.А.</copyright-holder><copyright-holder xml:lang="en">Erokhin M.M., Kozelchuk N.Y., Ziganshin R.H., Tatarskiy V.V., Chetverina D.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vavilov.elpub.ru/jour/article/view/4802">https://vavilov.elpub.ru/jour/article/view/4802</self-uri><abstract><p>Транскрипционные факторы относятся к одной из главных групп белков, подавление активности которых приводит к остановке роста опухолей. В различных типах рака экспрессируется определенный набор транскрипционных факторов, которые создают и поддерживают специфические паттерны экспрессии генов. В клетках рака простаты ключевым транскрипционным регулятором является белок HOXB13 (Homeobox B13). Известно, что HOXB13 – важный регулятор эмбрионального развития и терминальной клеточной дифференцировки. Он регулирует транскрипцию многих генов в нормальных и трансформированных клетках простаты, а также способен действовать как пионерный фактор, который открывает хроматин в регуляторных областях генов. Однако данных о белковых партнерах и функциях HOXB13 в клетках рака простаты очень мало. В настоящей работе мы провели поиск белковых партнеров HOXB13 методом иммуноаффинной очистки с последующим высокопроизводительным масс-спектрометрическим анализом (IP/LC-MS), используя в качестве модели клеточную линию рака простаты PC-3. Было обнаружено, что основными партнерами HOXB13 являются транскрипционные факторы с разными типами ДНК-связывающих доменов, в том числе белки TBX3, TBX2, ZFHX4, ZFHX3, RUNX1, NFAT5. С помощью ресурса DepMap мы показали, что один из установленных партнеров, белок TBX3, как и HOXB13, критически важен для роста и пролиферации клеточных линий рака простаты in vitro. Анализ отдельных клеточных линий рака простаты выявил, что нокаут обоих генов, HOXB13 и TBX3, приводит к гибели одних и тех же линий: VCaP, LNCaP (clone FGC), PC-3 и 22Rv1. Таким образом, HOXB13 и TBX3 могут совместно рассматриваться как потенциальные мишени для создания специфических ингибиторов, подавляющих рост клеток рака простаты.</p></abstract><trans-abstract xml:lang="en"><p>Transcription factors represent one of the major groups of proteins, whose suppression leads to tumor growth arrest. Different types of cancer express a specific set of transcription factors that create and maintain unique patterns of gene expression. In prostate cancer cells, one of the key transcriptional regulators is the HOXB13 (Homeobox B13) protein. HOXB13 is known to be an important regulator of embryonic development and terminal cell differentiation. HOXB13 regulates the transcription of many genes in normal and transformed prostate cells and is also capable of acting as a pioneer factor that opens chromatin in the regulatory regions of genes. However, little is known about the protein partners and functions of HOXB13 in prostate cells. In the present study, we searched for protein partners of HOXB13 by immunoaffinity purification followed by high-throughput mass spectrometric analysis (IP/LC-MS) using the PC-3 prostate cancer cell line as a model. The main partners of HOXB13 were found to be transcription factors with different types of DNA-binding domains, including the TBX3, TBX2, ZFHX4, ZFHX3, RUNX1, NFAT5 proteins. Using the DepMap resource, we have shown that one of the identified partners, the TBX3 protein is as critical for the growth and proliferation of prostate cancer cell lines in vitro as HOXB13. Analysis of individual prostate cancer cell lines revealed that knockout of both genes, HOXB13 and TBX3, leads to the death of the same lines: VCaP, LNCaP (clone FGC), PC-3 and 22Rv1. Thus, HOXB13 and TBX3 can be considered together as potential targets for the development of specific inhibitors that suppress prostate cancer cell growth.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак простаты</kwd><kwd>транскрипционные факторы</kwd><kwd>регуляция транскрипции</kwd><kwd>HOXB13</kwd><kwd>TBX3</kwd><kwd>TBX2</kwd><kwd>ZFHX4</kwd><kwd>ZFHX3</kwd><kwd>RUNX1</kwd><kwd>NFAT5</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>transcription factors</kwd><kwd>regulation of transcription</kwd><kwd>HOXB13</kwd><kwd>TBX3</kwd><kwd>TBX2</kwd><kwd>ZFHX4</kwd><kwd>ZFHX3</kwd><kwd>RUNX1</kwd><kwd>NFAT5</kwd></kwd-group><funding-group xml:lang="en"><funding-statement>The study was supported by Russian Science Foundation grant No. 20-74-10099</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Adashek J.J., Leonard A., Roszik J., Menta A.K., Genovese G., Subbiah V., Msaouel P. Cancer genetics and therapeutic opportunities in urologic practice. Cancers (Basel). 2020;12(3):710. doi 10.3390/cancers12030710</mixed-citation><mixed-citation xml:lang="en">Adashek J.J., Leonard A., Roszik J., Menta A.K., Genovese G., Subbiah V., Msaouel P. Cancer genetics and therapeutic opportunities in urologic practice. Cancers (Basel). 2020;12(3):710. doi 10.3390/cancers12030710</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bartha Á., Győrffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622. doi 10.3390/ijms22052622</mixed-citation><mixed-citation xml:lang="en">Bartha Á., Győrffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622. doi 10.3390/ijms22052622</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bouhlel M.A., Lambert M., David-Cordonnier M.-H. Targeting transcription factor binding to DNA by competing with DNA binders as an approach for controlling gene expression. Curr Top Med Chem. 2015;15(14):1323-1358. doi 10.2174/1568026615666150413154713</mixed-citation><mixed-citation xml:lang="en">Bouhlel M.A., Lambert M., David-Cordonnier M.-H. Targeting transcription factor binding to DNA by competing with DNA binders as an approach for controlling gene expression. Curr Top Med Chem. 2015;15(14):1323-1358. doi 10.2174/1568026615666150413154713</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bushweller J.H. Targeting transcription factors in cancer – from undruggable to reality. Nat Rev Cancer. 2019;19(11):611-624. doi 10.1038/s41568-019-0196-7</mixed-citation><mixed-citation xml:lang="en">Bushweller J.H. Targeting transcription factors in cancer – from undruggable to reality. Nat Rev Cancer. 2019;19(11):611-624. doi 10.1038/s41568-019-0196-7</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cai Q., Wang X., Li X., Gong R., Guo X., Tang Y., Yang K., Niu Y., Zhao Y. Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates. Oncotarget. 2015;6(39):42312-42321. doi 10.18632/oncotarget.5994</mixed-citation><mixed-citation xml:lang="en">Cai Q., Wang X., Li X., Gong R., Guo X., Tang Y., Yang K., Niu Y., Zhao Y. Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates. Oncotarget. 2015;6(39):42312-42321. doi 10.18632/oncotarget.5994</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cao Q., Wang X., Zhao M., Yang R., Malik R., Qiao Y., Poliakov A., … Feng F.Y., Kalantry S., Qin Z.S., Dhanasekaran S.M., Chinnaiyan A.M. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014;5:3127. doi 10.1038/ncomms4127</mixed-citation><mixed-citation xml:lang="en">Cao Q., Wang X., Zhao M., Yang R., Malik R., Qiao Y., Poliakov A., … Feng F.Y., Kalantry S., Qin Z.S., Dhanasekaran S.M., Chinnaiyan A.M. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014;5:3127. doi 10.1038/ncomms4127</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chetverina D., Vorobyeva N.E., Mazina M.Y., Fab L.V., Lomaev D., Golovnina A., Mogila V., Georgiev P., Ziganshin R.H., Erokhin M. Comparative interactome analysis of the PRE DNA-binding factors: purification of the Combgap-, Zeste-, Psq-, and Adf1-associated proteins. Cell Mol Life Sci. 2022;79(7):353. doi 10.1007/s00018-022-04383-2</mixed-citation><mixed-citation xml:lang="en">Chetverina D., Vorobyeva N.E., Mazina M.Y., Fab L.V., Lomaev D., Golovnina A., Mogila V., Georgiev P., Ziganshin R.H., Erokhin M. Comparative interactome analysis of the PRE DNA-binding factors: purification of the Combgap-, Zeste-, Psq-, and Adf1-associated proteins. Cell Mol Life Sci. 2022;79(7):353. doi 10.1007/s00018-022-04383-2</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chetverina D., Vorobyeva N.E., Gyorffy B., Shtil A.A., Erokhin M. Analyses of genes critical to tumor survival reveal potential ‘supertargets’: focus on transcription. Cancers (Basel). 2023;15(11):3042. doi 10.3390/cancers15113042</mixed-citation><mixed-citation xml:lang="en">Chetverina D., Vorobyeva N.E., Gyorffy B., Shtil A.A., Erokhin M. Analyses of genes critical to tumor survival reveal potential ‘supertargets’: focus on transcription. Cancers (Basel). 2023;15(11):3042. doi 10.3390/cancers15113042</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Crona D.J., Whang Y.E. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 2017;9(6):67. doi 10.3390/cancers9060067</mixed-citation><mixed-citation xml:lang="en">Crona D.J., Whang Y.E. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 2017;9(6):67. doi 10.3390/cancers9060067</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Erokhin M., Georgiev P., Chetverina D. Drosophila DNA-binding proteins in polycomb repression. Epigenomes. 2018;2(1):1. doi 10.3390/epigenomes2010001</mixed-citation><mixed-citation xml:lang="en">Erokhin M., Georgiev P., Chetverina D. Drosophila DNA-binding proteins in polycomb repression. Epigenomes. 2018;2(1):1. doi 10.3390/epigenomes2010001</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ewing C.M., Ray A.M., Lange E.M., Zuhlke K.A., Robbins C.M., Tembe W.D., Wiley K.E., … Montie J.E., Xu J., Carpten J.D., Isaacs W.B., Cooney K.A. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141-149. doi 10.1056/NEJMoa1110000</mixed-citation><mixed-citation xml:lang="en">Ewing C.M., Ray A.M., Lange E.M., Zuhlke K.A., Robbins C.M., Tembe W.D., Wiley K.E., … Montie J.E., Xu J., Carpten J.D., Isaacs W.B., Cooney K.A. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141-149. doi 10.1056/NEJMoa1110000</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Feng Y., Zhang T., Wang Y., Xie M., Ji X., Luo X., Huang W., Xia L. Homeobox genes in cancers: from carcinogenesis to recent therapeutic intervention. Front Oncol. 2021;11:770428. doi 10.3389/fonc.2021.770428</mixed-citation><mixed-citation xml:lang="en">Feng Y., Zhang T., Wang Y., Xie M., Ji X., Luo X., Huang W., Xia L. Homeobox genes in cancers: from carcinogenesis to recent therapeutic intervention. Front Oncol. 2021;11:770428. doi 10.3389/fonc.2021.770428</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Goldman M.J., Craft B., Hastie M., Repečka K., McDade F., Kamath A., Banerjee A., Luo Y., Rogers D., Brooks A.N., Zhu J., Haussler D. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675-678. doi 10.1038/s41587-020-0546-8</mixed-citation><mixed-citation xml:lang="en">Goldman M.J., Craft B., Hastie M., Repečka K., McDade F., Kamath A., Banerjee A., Luo Y., Rogers D., Brooks A.N., Zhu J., Haussler D. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675-678. doi 10.1038/s41587-020-0546-8</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hagenbuchner J., Ausserlechner M.J. Targeting transcription factors by small compounds – current strategies and future implications. Biochem Pharmacol. 2016;107:1-13. doi 10.1016/j.bcp.2015.12.006</mixed-citation><mixed-citation xml:lang="en">Hagenbuchner J., Ausserlechner M.J. Targeting transcription factors by small compounds – current strategies and future implications. Biochem Pharmacol. 2016;107:1-13. doi 10.1016/j.bcp.2015.12.006</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hankey W., Chen Z., Wang Q. Shaping chromatin states in prostate cancer by pioneer transcription factors. Cancer Res. 2020;80(12): 2427-2436. doi 10.1158/0008-5472.CAN-19-3447</mixed-citation><mixed-citation xml:lang="en">Hankey W., Chen Z., Wang Q. Shaping chromatin states in prostate cancer by pioneer transcription factors. Cancer Res. 2020;80(12): 2427-2436. doi 10.1158/0008-5472.CAN-19-3447</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hayward S.W., Dahiya R., Cunha G.R., Bartek J., Deshpande N., Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim. 1995;31(1):14-24. doi 10.1007/BF02631333</mixed-citation><mixed-citation xml:lang="en">Hayward S.W., Dahiya R., Cunha G.R., Bartek J., Deshpande N., Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim. 1995;31(1):14-24. doi 10.1007/BF02631333</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hubert K.A., Wellik D.M. Hox genes in development and beyond. Development. 2023;150(1):dev192476. doi 10.1242/dev.192476</mixed-citation><mixed-citation xml:lang="en">Hubert K.A., Wellik D.M. Hox genes in development and beyond. Development. 2023;150(1):dev192476. doi 10.1242/dev.192476</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang J.H., Arafeh R., Seo J.-H., Baca S.C., Ludwig M., Arnoff T.E., Sawyer L., … Kregel S., Van Allen E.M., Drake J.M., Freedman M.L., Hahn W.C. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. eLife. 2022;11:e73223. doi 10.7554/eLife.73223</mixed-citation><mixed-citation xml:lang="en">Hwang J.H., Arafeh R., Seo J.-H., Baca S.C., Ludwig M., Arnoff T.E., Sawyer L., … Kregel S., Van Allen E.M., Drake J.M., Freedman M.L., Hahn W.C. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. eLife. 2022;11:e73223. doi 10.7554/eLife.73223</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Jolma A., Yan J., Whitington T., Toivonen J., Nitta K.R., Rastas P., Morgunova E., … Hughes T.R., Lemaire P., Ukkonen E., Kivioja T., Taipale J. DNA-binding specificities of human transcription factors. Cell. 2013;152(1-2):327-339. doi 10.1016/j.cell.2012.12.009</mixed-citation><mixed-citation xml:lang="en">Jolma A., Yan J., Whitington T., Toivonen J., Nitta K.R., Rastas P., Morgunova E., … Hughes T.R., Lemaire P., Ukkonen E., Kivioja T., Taipale J. DNA-binding specificities of human transcription factors. Cell. 2013;152(1-2):327-339. doi 10.1016/j.cell.2012.12.009</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jolma A., Yin Y., Nitta K.R., Dave K., Popov A., Taipale M., Enge M., Kivioja T., Morgunova E., Taipale J. DNA-dependent formation of transcription factor pairs alters their binding specificity. Nature. 2015;527(7578):384-388. doi 10.1038/nature15518</mixed-citation><mixed-citation xml:lang="en">Jolma A., Yin Y., Nitta K.R., Dave K., Popov A., Taipale M., Enge M., Kivioja T., Morgunova E., Taipale J. DNA-dependent formation of transcription factor pairs alters their binding specificity. Nature. 2015;527(7578):384-388. doi 10.1038/nature15518</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Khan S.F., Damerell V., Omar R., Du Toit M., Khan M., Maranyane H.M., Mlaza M., Bleloch J., Bellis C., Sahm B.D.B., Peres J., ArulJothi K.N., Prince S. The roles and regulation of TBX3 in development and disease. Gene. 2020;726:144223. doi 10.1016/j.gene. 2019.144223</mixed-citation><mixed-citation xml:lang="en">Khan S.F., Damerell V., Omar R., Du Toit M., Khan M., Maranyane H.M., Mlaza M., Bleloch J., Bellis C., Sahm B.D.B., Peres J., ArulJothi K.N., Prince S. The roles and regulation of TBX3 in development and disease. Gene. 2020;726:144223. doi 10.1016/j.gene. 2019.144223</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lambert M., Jambon S., Depauw S., David-Cordonnier M.-H. Targeting transcription factors for cancer treatment. Molecules. 2018; 23(6):1479. doi 10.3390/molecules23061479</mixed-citation><mixed-citation xml:lang="en">Lambert M., Jambon S., Depauw S., David-Cordonnier M.-H. Targeting transcription factors for cancer treatment. Molecules. 2018; 23(6):1479. doi 10.3390/molecules23061479</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lang S.H., Smith J., Hyde C., Macintosh C., Stower M., Maitland N.J. Differentiation of prostate epithelial cell cultures by materigel/stromal cell glandular reconstruction. In Vitro Cell Dev Biol Anim. 2006;42(8):273-280. doi 10.1290/0511080.1</mixed-citation><mixed-citation xml:lang="en">Lang S.H., Smith J., Hyde C., Macintosh C., Stower M., Maitland N.J. Differentiation of prostate epithelial cell cultures by materigel/stromal cell glandular reconstruction. In Vitro Cell Dev Biol Anim. 2006;42(8):273-280. doi 10.1290/0511080.1</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Song J., Zhou P., Zhou J., Xie S. Targeting undruggable transcription factors with PROTACs: advances and perspectives. J Med Chem. 2022;65(15):10183-10194. doi 10.1021/acs.jmedchem.2c00691</mixed-citation><mixed-citation xml:lang="en">Li Y., Song J., Zhou P., Zhou J., Xie S. Targeting undruggable transcription factors with PROTACs: advances and perspectives. J Med Chem. 2022;65(15):10183-10194. doi 10.1021/acs.jmedchem.2c00691</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lingbeek M.E., Jacobs J.J.L., van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J Biol Chem. 2002; 277(29):26120-26127. doi 10.1074/jbc.M200403200</mixed-citation><mixed-citation xml:lang="en">Lingbeek M.E., Jacobs J.J.L., van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J Biol Chem. 2002; 277(29):26120-26127. doi 10.1074/jbc.M200403200</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ortiz-Lombardia M., Foos N., Maurel-Zaffran C., Saurin A.J., Graba Y. Hox functional diversity: novel insights from flexible motif folding and plastic protein interaction. BioEssays. 2017;39(4):1600246. doi 10.1002/bies.201600246</mixed-citation><mixed-citation xml:lang="en">Ortiz-Lombardia M., Foos N., Maurel-Zaffran C., Saurin A.J., Graba Y. Hox functional diversity: novel insights from flexible motif folding and plastic protein interaction. BioEssays. 2017;39(4):1600246. doi 10.1002/bies.201600246</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Pomerantz M.M., Qiu X., Zhu Y., Takeda D.Y., Pan W., Baca S.C., Gusev A., … Lee G.-S.M., Corey E., Long H.W., Zwart W., Freedman M.L. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020;52(8): 790-799. doi 10.1038/s41588-020-0664-8</mixed-citation><mixed-citation xml:lang="en">Pomerantz M.M., Qiu X., Zhu Y., Takeda D.Y., Pan W., Baca S.C., Gusev A., … Lee G.-S.M., Corey E., Long H.W., Zwart W., Freedman M.L. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020;52(8): 790-799. doi 10.1038/s41588-020-0664-8</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Schuettengruber B., Bourbon H.-M., Di Croce L., Cavalli G. Genome regulation by Polycomb and Trithorax: 70 years and counting. Cell. 2017;171(1):34-57. doi 10.1016/j.cell.2017.08.002</mixed-citation><mixed-citation xml:lang="en">Schuettengruber B., Bourbon H.-M., Di Croce L., Cavalli G. Genome regulation by Polycomb and Trithorax: 70 years and counting. Cell. 2017;171(1):34-57. doi 10.1016/j.cell.2017.08.002</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi 10.3322/caac.21763</mixed-citation><mixed-citation xml:lang="en">Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi 10.3322/caac.21763</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Tsherniak A., Vazquez F., Montgomery P.G., Weir B.A., Kryukov G., Cowley G.S., Gill S., … Garraway L.A., Root D.E., Golub T.R., Boehm J.S., Hahn W.C. Defining a cancer dependency map. Cell. 2017;170(3):564-576.e16. doi 10.1016/j.cell.2017.06.010</mixed-citation><mixed-citation xml:lang="en">Tsherniak A., Vazquez F., Montgomery P.G., Weir B.A., Kryukov G., Cowley G.S., Gill S., … Garraway L.A., Root D.E., Golub T.R., Boehm J.S., Hahn W.C. Defining a cancer dependency map. Cell. 2017;170(3):564-576.e16. doi 10.1016/j.cell.2017.06.010</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Vazquez F., Sellers W.R. Are CRISPR screens providing the next generation of therapeutic targets? Cancer Res. 2021;81(23):5806- 5809. doi 10.1158/0008-5472.CAN-21-1784</mixed-citation><mixed-citation xml:lang="en">Vazquez F., Sellers W.R. Are CRISPR screens providing the next generation of therapeutic targets? Cancer Res. 2021;81(23):5806- 5809. doi 10.1158/0008-5472.CAN-21-1784</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Vishnoi K., Viswakarma N., Rana A., Rana B. Transcription factors in cancer development and therapy. Cancers (Basel). 2020;12(8): 2296. doi 10.3390/cancers12082296</mixed-citation><mixed-citation xml:lang="en">Vishnoi K., Viswakarma N., Rana A., Rana B. Transcription factors in cancer development and therapy. Cancers (Basel). 2020;12(8): 2296. doi 10.3390/cancers12082296</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Webber M.M., Quader S.T.A., Kleinman H.K., Bello‐DeOcampo D., Storto P.D., Bice G., DeMendonca‐Calaca W., Williams D.E. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate. 2001;47(1):1-13. doi 10.1002/pros.1041</mixed-citation><mixed-citation xml:lang="en">Webber M.M., Quader S.T.A., Kleinman H.K., Bello‐DeOcampo D., Storto P.D., Bice G., DeMendonca‐Calaca W., Williams D.E. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate. 2001;47(1):1-13. doi 10.1002/pros.1041</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Weiner A.B., Faisal F.A., Davicioni E., Karnes R.J., Griend D.J.V., Lotan T.L., Schaeffer E.M. Somatic HOXB13 expression correlates with metastatic progression in men with localized prostate cancer following radical prostatectomy. Eur Urol Oncol. 2021;4(6):955- 962. doi 10.1016/j.euo.2020.05.001</mixed-citation><mixed-citation xml:lang="en">Weiner A.B., Faisal F.A., Davicioni E., Karnes R.J., Griend D.J.V., Lotan T.L., Schaeffer E.M. Somatic HOXB13 expression correlates with metastatic progression in men with localized prostate cancer following radical prostatectomy. Eur Urol Oncol. 2021;4(6):955- 962. doi 10.1016/j.euo.2020.05.001</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Xie X., Yu T., Li X., Zhang N., Foster L.J., Peng C., Huang W., He G. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduct Target Ther. 2023;8(1): 335. doi 10.1038/s41392-023-01589-z</mixed-citation><mixed-citation xml:lang="en">Xie X., Yu T., Li X., Zhang N., Foster L.J., Peng C., Huang W., He G. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduct Target Ther. 2023;8(1): 335. doi 10.1038/s41392-023-01589-z</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Yao J., Chen Y., Nguyen D.T., Thompson Z.J., Eroshkin A.M., Nerlakanti N., Patel A.K., … Coppola D., Zhang J., Perera R., Kim Y., Mahajan K. The homeobox gene, HOXB13, regulates a mitotic protein-kinase interaction network in metastatic prostate cancers. Sci Rep. 2019;9(1):9715. doi 10.1038/s41598-019-46064-4</mixed-citation><mixed-citation xml:lang="en">Yao J., Chen Y., Nguyen D.T., Thompson Z.J., Eroshkin A.M., Nerlakanti N., Patel A.K., … Coppola D., Zhang J., Perera R., Kim Y., Mahajan K. The homeobox gene, HOXB13, regulates a mitotic protein-kinase interaction network in metastatic prostate cancers. Sci Rep. 2019;9(1):9715. doi 10.1038/s41598-019-46064-4</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Yarosh W., Barrientos T., Esmailpour T., Lin L., Carpenter P.M., Osann K., Anton-Culver H., Huang T. TBX3 is overexpressed in breast cancer and represses p14ARF by interacting with histone deacetylases. Cancer Res. 2008;68(3):693-699. doi 10.1158/0008-5472.CAN-07-5012</mixed-citation><mixed-citation xml:lang="en">Yarosh W., Barrientos T., Esmailpour T., Lin L., Carpenter P.M., Osann K., Anton-Culver H., Huang T. TBX3 is overexpressed in breast cancer and represses p14ARF by interacting with histone deacetylases. Cancer Res. 2008;68(3):693-699. doi 10.1158/0008-5472.CAN-07-5012</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Yu M., Mazor T., Huang H., Huang H.-T., Kathrein K.L., Woo A.J., Chouinard C.R., … Roeder R.G., Kim C.F., Zon L.I., Fraenkel E., Cantor A.B. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012; 45(3):330-343. doi 10.1016/j.molcel.2011.11.032</mixed-citation><mixed-citation xml:lang="en">Yu M., Mazor T., Huang H., Huang H.-T., Kathrein K.L., Woo A.J., Chouinard C.R., … Roeder R.G., Kim C.F., Zon L.I., Fraenkel E., Cantor A.B. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012; 45(3):330-343. doi 10.1016/j.molcel.2011.11.032</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Zabalza C.V., Adam M., Burdelski C., Wilczak W., Wittmer C., Kraft S., Krech T., … Minner S., Simon R., Sauter G., Schlomm T., Tsourlakis M.C. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget. 2015;6(14):12822-12834. doi 10.18632/oncotarget.3431</mixed-citation><mixed-citation xml:lang="en">Zabalza C.V., Adam M., Burdelski C., Wilczak W., Wittmer C., Kraft S., Krech T., … Minner S., Simon R., Sauter G., Schlomm T., Tsourlakis M.C. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget. 2015;6(14):12822-12834. doi 10.18632/oncotarget.3431</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J., Lee D., Dhiman V., Jiang P., Xu J., McGillivray P., Yang H., … Cheng C., Yue F., Liu X.S., White K.P., Gerstein M. An integrative ENCODE resource for cancer genomics. Nat Commun. 2020;11(1):3696. doi 10.1038/s41467-020-14743-w</mixed-citation><mixed-citation xml:lang="en">Zhang J., Lee D., Dhiman V., Jiang P., Xu J., McGillivray P., Yang H., … Cheng C., Yue F., Liu X.S., White K.P., Gerstein M. An integrative ENCODE resource for cancer genomics. Nat Commun. 2020;11(1):3696. doi 10.1038/s41467-020-14743-w</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Zhuang J.-J., Liu Q., Wu D.-L., Tie L. Current strategies and progress for targeting the “undruggable” transcription factors. Acta Pharmacol Sin. 2022;43(10):2474-2481. doi 10.1038/s41401-021-00852-9</mixed-citation><mixed-citation xml:lang="en">Zhuang J.-J., Liu Q., Wu D.-L., Tie L. Current strategies and progress for targeting the “undruggable” transcription factors. Acta Pharmacol Sin. 2022;43(10):2474-2481. doi 10.1038/s41401-021-00852-9</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
